Amgen Inc.

History

Year	Detail
1980	Amgen was founded as Applied Molecular Genetics Inc. as the brainchild of venture capitalists William K. Bowes and associates.
1984	Kirin and Amgen formed a joint venture, Kirin-Amgen, to commercialize erythropoietin worldwide.
1985	Applied Molecular Genetics Inc. developed the company's second blockbuster drug, NEUPOGEN (filgrastim).
1989	FDA approved EPOGEN (epoetin alfa), EPOGEN is named Product of the Year, by Fortune magazine. In the same year it established its European headquarters in Lucerne, Switzerland.
1993	The company has opened its Puerto Rico facility, which has become Amgen's flagship manufacturing site with over 1.7 million square feet of space.
1998	FDA approves Enbrel (etanercept).
1999	Amgen Scientists identify and clone osteoprotegerin (OPG).
2001	Amgen's Cambridge, Massachusetts research center opens and the same year Aranesp (darbepoetin alfa) is approved by the FDA.
2001	Amgen and NASA team up to study Amgen's investigational treatment, osteoprotegerin (OPG), on the space shuttle Endeavour.
2002	The company acquires Immunex, the developer of ENBREL (etanercept), along with a manufacturing plant in Rhode Island and in the same year Neulasta (pegfilgrastim) is approved by the FDA.
2004	Amgen acquired Tularik, establishing a strong presence in South San Francisco, and in the same year, Sensipar (cinacalcet) was approved by the FDA.
2010	Prolia (denosumab) and XGEVA (denosumab) are approved by the FDA
2011	Amgen, CDC, and CDC Foundation partner to improve infection control for cancer patients.
2011	The company acquired a manufacturing facility near Dublin, Ireland, and acquired the company BioVex, developers of talimogene laherparepvec, and expanded in Brazil, including the acquisition of Bergamo, a privately held Brazilian pharmaceutical company.
2012	Amgen acquired deCODE Genetics, a global company in human genetics, and Amgen Teach launched in Europe.
2013	The company Amgen Astellas BioPharma K.K. alliance forms in Japan and Amgen-Betta Pharmaceuticals joint venture is established in China and it also acquired Onyx Pharmaceuticals, developers of Kyprolis® (carfilzomib) for Injection.
2014	Amgen's Asia Research and Development Center opens at ShanghaiTech University in China.
2015	Amgen's first commercial chemical synthesis manufacturing facility opens in Singapore and Corlanor (ivabradine), IMLYGIC (talimogene laherparepvec) and Repatha (evolocumab) are approved by the FDA.
2017	The company has opened its Amgen Capability Center (ACC) in Tampa, Florida and also launched the ENBREL (etanercept) Mini single-dose prefilled cartridge with AutoTouch Reusable Autoinjector that is ergonomically designed for patients.
2018	Amgen established its new next-generation biomanufacturing plant at its West Greenwich, Rhode Island campus.
2019	It has completed the acquisition of Otezla (apremilast).
2020	Amgen announced a strategic collaboration with BeiGene to expand its oncology presence in China and established a Wholly-Owned Affiliate In Japan.